| 0 (0%) | 02-28 14:04 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 136.43 |
1-year : | 159.36 |
| Resists | First : | 116.81 |
Second : | 136.43 |
| Pivot price | 113.26 |
|||
| Supports | First : | 109.68 |
Second : | 105.26 |
| MAs | MA(5) : | 115.43 |
MA(20) : | 112.2 |
| MA(100) : | 122.11  |
MA(250) : | 126.73 |
|
| MACD | MACD : | -0.2 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 91.5 |
D(3) : | 91.4 |
| RSI | RSI(14): 56.8 |
|||
| 52-week | High : | 138.62 | Low : | 105.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABT ] has closed below upper band by 6.5%. Bollinger Bands are 28.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 116.71 - 117.14 | 117.14 - 117.49 |
| Low: | 113.33 - 113.88 | 113.88 - 114.32 |
| Close: | 115.43 - 116.28 | 116.28 - 116.97 |
Sat, 28 Feb 2026
ABT’s RS7 Legacy Edition Is One Great Way To Mourn the Audi RS 7 - autoevolution
Sat, 28 Feb 2026
Harvest Portfolios Group Inc. Raises Stake in Abbott Laboratories $ABT - MarketBeat
Fri, 27 Feb 2026
Final Trade: GOOGL, TGT, ABT, IJR - CNBC
Fri, 27 Feb 2026
FDA Greenlights Abbott's (ABT) CardioMEMS Hero for Heart Failure Management - GuruFocus
Thu, 26 Feb 2026
Assessing Abbott Laboratories (ABT) Valuation After Mixed Share Performance And Conflicting Fair Value Signals - Yahoo Finance
Thu, 26 Feb 2026
Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 1,740 (M) |
| Shares Float | 1,730 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 81.8 (%) |
| Shares Short | 18,730 (K) |
| Shares Short P.Month | 17,400 (K) |
| EPS | 3.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 29.29 |
| Profit Margin | 14.7 % |
| Operating Margin | 22 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 13.1 % |
| Qtrly Rev. Growth | 4.4 % |
| Gross Profit (p.s.) | 14.44 |
| Sales Per Share | 25.47 |
| EBITDA (p.s.) | 6.6 |
| Qtrly Earnings Growth | -80.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 31.17 |
| PEG Ratio | 0 |
| Price to Book value | 3.96 |
| Price to Sales | 4.56 |
| Price to Cash Flow | 0 |
| Dividend | 0.62 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|